Peptides: The Science, Uses & Safety | Dr. Abud Bakri — Key Takeaways
YouTube
Peptides: The Science, Uses & Safety | Dr. Abud Bakri
Andrew Huberman2h 48mJun 1, 2026
Watch the originalBPC-157's most credible use case is gut protection and repair — the gastric data is mechanistically coherent, but all animal evidence comes from one Croatian research group, and no completed human RCT exists.
Key takeaways
All compounded peptide APIs originate from China — no US-made peptides exist
All compounded peptide APIs originate from China — no US-made peptides exist
- Semiglutide, retatrutide, BPC-157 — raw synthesized material is Chinese regardless of whether it's compounded, gray market, or pharma-finished.
- Compounding pharmacy quality varies widely; batch-to-batch inconsistency is the primary risk vector, not the molecule itself.
BPC-157 has no identified receptor — mechanism is unknown
BPC-157 has no identified receptor — mechanism is unknown
- Unlike GLP-1s with clear receptor targets, BPC-157 may work via epigenetic chromatin modification or protein cross-linking.
- No LD50 exists for BPC-157 in animals — this absence of toxicity data blocks FDA approval pathways.
BPC-157 acetate is banned (Category 2); PDA arginate is the legal workaround
BPC-157 acetate is banned (Category 2); PDA arginate is the legal workaround
- FDA moved BPC-157 acetate to Category 2 (do not compound) in late 2024; compounders relabeled it as pentadecapeptide arginate (PDA) — same molecule.
- Legal status is state-by-state; telehealth prescriptions are governed by the patient's state, not the prescribing physician's state.
This Dig holds 4 more insights, 4 flashcards, and 2 quotes — free in Homestake.
Unlock this Dig freeFree forever · No credit card required
In this video
- 1mIntroduction: What Are Peptides and How to Categorize Them
- 10mBPC-157: Origins, Discovery, and History
- 25mBPC-157: Mechanisms of Action and Animal Research
- 47mBPC-157: Legal Status, FDA Regulations, and Compounding Pharmacies
- 1h 10mGLP-1 Agonists: Shortage, Compounding, and Market Dynamics
- 1h 30mGray Market and Black Market Peptides: Sourcing and Safety
- 1h 48mBPC-157: Safety Profile, Adverse Events, and Cancer Risk
- 2h 5mBPC-157: Anecdotal Evidence, Personal Experiences, and Clinical Potential
- 2h 27mPhysician Liability, Patient Rights, and the Future of Peptide Medicine
This page is a partial, transformative summary produced by Homestake. All rights to the original content remain with its creator — please support them at the source link above.